Genmab A/S to acquire ProfoundBio, Inc. to broaden and strengthen its oncology portfolio
04/03/24, 5:44 AM
Location
copenhagen
woodinvilleIndustry
therapeutics
biotechnology
health care
biotechnology
Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have entered into a definitive agreement for an all-cash transaction valued at USD 1.8 billion. The acquisition will further broaden Genmab’s mid- to late-stage clinical pipeline and strengthen its suite of proprietary technology platforms. Genmab's acquisition of ProfoundBio's next-generation ADCs and ADC technologies aims to create new opportunities in the treatment of cancer, particularly in gynecologic oncology and solid tumors.
Company Info
Location
Copenhagen, Capital Region Of Denmark, Denmark
Company info
Genmab A/S is a publicly traded biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. It has a validated suite of proprietary technology platforms and a mid- to late-stage clinical pipeline. The company is committed to impacting the lives of patients through innovative antibody medicines.
Unlock Strategic Intelligence with Fundz
Access real-time funding updates, strategic shifts with FundzWatch™, exclusive Family Offices, and more — helping you close deals and seize opportunities faster.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.
Related people
H
AH